There are for example well-known differences in the regulation of CDK4/6 and CDK2 activities between normal and cancer cells, and our study may serve as a roadmap how simultaneous CDK4/6 and CDK2 reporter analysis can be applied to understand therapeutically relevant signaling differences between normal and cancer cells. Here, CDK2 is linked to cancer.